Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers
Main Authors: | Brem, Steven, Meyers, Christina A, Palmer, Gary, Booth-Jones, Margaret, Jain, Surbhi, Ewend, Matthew G |
---|---|
Format: | Online |
Language: | English |
Published: |
Blackwell Publishing Ltd
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209121/ |
Similar Items
-
The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
by: Lombardi, Giuseppe, et al.
Published: (2014) -
Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors
by: Ene, Chibawanye I., et al.
Published: (2016) -
NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice
by: Price, Stephen J., et al.
Published: (2012) -
Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide
by: Kleinberg, Lawrence
Published: (2012) -
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis
by: Chowdhary, Sajeel A., et al.
Published: (2015)